APC5 Antibody

What is the biological function of APC5 and why is it important to study?

APC5 (ANAPC5) functions as a component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle . The APC/C complex primarily mediates the formation of 'Lys-11'-linked polyubiquitin chains, and to a lesser extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains . Additionally, the complex catalyzes the assembly of branched 'Lys-11'-/'Lys-48'-linked ubiquitin chains on target proteins . Understanding APC5 is crucial for elucidating cell cycle regulation mechanisms, which have implications for cancer research, developmental biology, and cellular homeostasis studies.

What considerations should guide my selection of an APC5 antibody for different experimental approaches?

When selecting an APC5 antibody, consider several critical factors based on your experimental needs. First, validate the antibody's reactivity with your species of interest; commercial APC5 antibodies have been validated for human, mouse, and rat samples . Second, ensure compatibility with your intended application—available antibodies are suitable for Western blotting (WB), immunofluorescence (IF), immunohistochemistry on paraffin-embedded tissues (IHC-P), and enzyme-linked immunosorbent assays (ELISA) . Third, consider antibody format: polyclonal antibodies like the rabbit polyclonal antibodies mentioned in the search results may provide stronger signals by recognizing multiple epitopes . Finally, verify the immunogen information—some antibodies are raised against specific peptide regions within APC5, which may influence epitope accessibility in different experimental conditions .

What is the expected molecular weight of APC5 in Western blotting and how do I interpret discrepancies?

The expected molecular weight of APC5 in Western blotting presents an interesting discrepancy between observed and calculated values. According to the search results, the observed molecular weight is approximately 68 kDa, while the calculated molecular weight is around 85 kDa . This difference could be attributed to several factors: post-translational modifications affecting protein migration, protein structure characteristics that influence SDS-PAGE mobility, or potential proteolytic processing in vivo.

When encountering such discrepancies, follow these methodological approaches:

• Compare your results with positive controls such as cell lines known to express full-length APC5 (e.g., HCT116 and HEK293)

• Use multiple antibodies targeting different regions of APC5 to confirm band identity

• Consider running gradient gels for better resolution of proteins in this molecular weight range

• Include phosphatase treatments of samples to assess whether post-translational modifications contribute to unexpected migration patterns

The significant difference between observed and calculated weights underscores the importance of thorough antibody validation rather than relying solely on predicted molecular weights.

How should I validate the specificity of an APC5 antibody in my experimental system?

Validating APC5 antibody specificity requires a multi-faceted approach as demonstrated in previous research . Implement these methodological strategies:

• Comparative Western blot analysis: Use a panel of antibodies directed against different regions of APC5 (N-terminal and C-terminal) and verify they detect the same protein band at the expected molecular weight . This cross-validation approach helps confirm identity.

• RNA interference validation: Transfect cells with siRNAs specifically targeting APC5 and confirm reduced protein levels by Western blotting. Include non-interfering siRNA controls to account for transfection effects .

• Immunoprecipitation-Western blot cross-validation: Perform immunoprecipitation with one APC5 antibody and detect the precipitated protein with another APC5 antibody . This approach confirms that different antibodies recognize the same protein.

• Control cell lines: Include positive controls (cell lines with known APC5 expression patterns) such as HCT116 and HEK293 (express full-length APC) and cell lines with truncated APC5 when available .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples. Specific binding should be competitively blocked, eliminating true signals while non-specific binding may persist.

This comprehensive validation strategy ensures reliable results and helps distinguish between specific signals and potential artifacts.

What are the essential controls for APC5 antibody experiments and why are they necessary?

Essential controls for APC5 antibody experiments safeguard against experimental artifacts and ensure reliable data interpretation. Based on established methodologies, implement these critical controls:

• Positive expression controls: Include cell lines with confirmed APC5 expression such as HCT116 (colorectal cancer cell line) and HEK293 (Human embryonic kidney), which express full-length APC . These standards establish expected signal patterns.

• Isotype-matched controls: For immunofluorescence or flow cytometry, include an irrelevant antibody of the same isotype (e.g., normal rabbit IgG for rabbit polyclonal antibodies) at the same concentration to identify non-specific binding . This reveals background attributable to antibody class.

• siRNA knockdown controls: Include both APC5-targeting siRNAs and non-interfering siRNA controls to verify signal specificity and account for non-specific transfection effects . Decreased signal with specific siRNA confirms antibody specificity.

• Secondary antibody-only controls: Omit primary antibody while maintaining all other steps to identify background from secondary antibody binding or autofluorescence.

• Cell cycle phase controls: Since APC5 functions in a cell cycle-dependent manner, include synchronized cell populations to observe expected changes in localization or activity.

These controls collectively establish signal specificity, distinguish true signals from artifacts, and provide context for correctly interpreting experimental outcomes.

How can I optimize Western blot conditions for detecting APC5 protein?

Optimizing Western blot conditions for APC5 detection requires attention to several critical parameters based on established methodologies :

• Gel concentration and separation conditions: Use 7.5% SDS-PAGE gels to achieve good separation of APC5 . For resolving full-length APC (314 kDa), lower percentage gels (5-6%) may be more appropriate.

• Protein transfer optimization:

  • Transfer to PVDF membrane in 2× Towbin buffer with 0.02% SDS or CAPS with 10% methanol

  • For higher molecular weight forms, perform transfer at 600 mA overnight for efficient transfer

  • Consider semi-dry transfer systems for the observed 68 kDa APC5 form

• Antibody concentration titration:

  • Test a range of antibody dilutions to find optimal signal-to-noise ratio

  • Starting points based on literature: Anti-Apc5 antibody at 1-2 μg/mL for Western blotting

• Signal detection optimization:

  • For human kidney tissue lysate, 15 μg of total protein provided detectable signal

  • Include positive control lysates from cells known to express APC5 (HCT116, HEK293)

• Blocking conditions optimization:

  • Test different blocking solutions (5% non-fat milk, 3-5% BSA)

  • Optimize blocking time (1-2 hours at room temperature or overnight at 4°C)

These methodological adjustments should be systematically tested to establish optimal conditions for specific experimental systems.

How can APC5 antibodies be employed to study protein-protein interactions within the APC/C complex?

APC5 antibodies offer powerful tools for investigating protein-protein interactions within the APC/C complex through these methodological approaches:

• Co-immunoprecipitation (Co-IP): Use APC5 antibodies to pull down the entire APC/C complex from cell lysates, followed by Western blot analysis with antibodies against other suspected interacting components . This technique preserves native protein complexes when performed under gentle lysis conditions.

• Sequential immunoprecipitation: Perform an initial IP with APC5 antibodies, elute under mild conditions, and then perform a second IP with antibodies against another APC/C component. This approach identifies proteins that exist in the same complex rather than just binary interactions.

• Proximity ligation assay (PLA): Use primary antibodies against APC5 and other potential interacting proteins followed by species-specific secondary antibodies conjugated to complementary oligonucleotides. When proteins are in close proximity (<40 nm), the oligonucleotides can be ligated and amplified, generating a fluorescent signal that can be quantified.

• Immunofluorescence co-localization: Employ different fluorescently labeled antibodies to visualize the co-localization of APC5 with other APC/C components in cells at different cell cycle stages. Advanced techniques like super-resolution microscopy can provide spatial resolution below the diffraction limit.

• Cross-linking followed by immunoprecipitation: Cross-link proteins in their native cellular environment before immunoprecipitation with APC5 antibodies to capture transient or weak interactions that might be lost during standard IP procedures.

These techniques can be combined to build a comprehensive understanding of APC/C complex assembly and dynamics under different cellular conditions.

What approaches can be used to investigate cell cycle-dependent changes in APC5 localization and function?

Investigating cell cycle-dependent changes in APC5 localization and function requires integrating multiple techniques:

• Synchronized cell population analysis: Synchronize cells at specific cell cycle phases (using thymidine block, nocodazole, or selective inhibitors) and analyze APC5 expression, modification, and localization at defined timepoints. This temporal approach reveals dynamic changes.

• Immunofluorescence microscopy in synchronized cells: Perform immunofluorescence with APC5 antibodies on synchronized cells, co-staining with cell cycle phase markers (e.g., cyclin B1 for G2/M) and counterstaining with DAPI to correlate APC5 localization with specific cell cycle phases.

• Live-cell imaging with fluorescently tagged APC5: Express fluorescently tagged APC5 at near-endogenous levels and validate localization with antibody staining. Then perform time-lapse imaging through the cell cycle, potentially using cell cycle phase sensors as reference markers.

• Flow cytometry with cell cycle analysis: Combine APC5 antibody staining with DNA content analysis (propidium iodide) to correlate APC5 levels or modifications with cell cycle phases across population distributions.

• Chromatin association analysis: Fractionate cells into cytoplasmic, nucleoplasmic, and chromatin-bound proteins at different cell cycle phases and analyze APC5 distribution using antibodies.

• Phase-specific immunoprecipitation: Immunoprecipitate APC5 from cells synchronized at different cell cycle phases and analyze co-precipitating proteins to identify phase-specific interaction partners.

These approaches collectively provide complementary insights into the spatial and functional dynamics of APC5 throughout the cell cycle.

How can APC5 antibodies be utilized to investigate the role of APC/C in ubiquitination pathways?

APC5 antibodies serve as valuable tools for dissecting the mechanistic details of APC/C-mediated ubiquitination pathways through these research strategies:

• IP-ubiquitination analysis: Immunoprecipitate APC/C using APC5 antibodies and probe for ubiquitinated substrates using ubiquitin antibodies. This identifies APC/C targets and reveals ubiquitination patterns. Since APC/C mediates the formation of predominantly 'Lys-11'-linked polyubiquitin chains , use linkage-specific ubiquitin antibodies to characterize chain types.

• In vitro ubiquitination assays: Purify APC/C by immunoprecipitation with APC5 antibodies and employ the complex in reconstituted ubiquitination reactions with purified E1, E2 enzymes, ubiquitin, and potential substrates. This controlled system allows manipulation of reaction components to determine requirements.

• Analysis of branched ubiquitin chains: Given that APC/C catalyzes assembly of branched 'Lys-11'-/'Lys-48'-linked ubiquitin chains , use APC5 antibodies to isolate the complex and study the formation of these specialized branched chains through mass spectrometry or linkage-specific antibodies.

• Cell cycle phase-specific ubiquitination: Synchronize cells at different cell cycle phases, immunoprecipitate with APC5 antibodies, and analyze ubiquitination patterns to determine how substrate targeting changes throughout the cell cycle.

• Proteasome inhibition studies: Treat cells with proteasome inhibitors before APC5 immunoprecipitation to stabilize ubiquitinated intermediates that would normally be rapidly degraded, enhancing detection of transient ubiquitination events.

These methodological approaches allow researchers to dissect the complex ubiquitination mechanisms mediated by the APC/C complex and identify regulatory points in this essential cellular pathway.

What methods can be used to investigate post-translational modifications of APC5?

Investigating post-translational modifications (PTMs) of APC5 requires specialized approaches leveraging antibody-based techniques:

• Modification-specific immunoprecipitation: Use general APC5 antibodies to immunoprecipitate all forms of APC5, then probe with antibodies specific for particular modifications (phosphorylation, ubiquitination, etc.) to detect modified forms. Conversely, immunoprecipitate with modification-specific antibodies and probe with APC5 antibodies.

• Phosphatase/deubiquitinase treatment: Treat immunoprecipitated APC5 with appropriate enzymes that remove specific modifications (phosphatases for phosphorylation, deubiquitinases for ubiquitination) and observe mobility shifts in subsequent Western blots using APC5 antibodies.

• Mass spectrometry analysis: Immunoprecipitate APC5 using validated antibodies and subject the purified protein to mass spectrometry analysis to identify and map all modifications simultaneously. This unbiased approach can reveal unexpected modifications.

• 2D gel electrophoresis: Separate proteins by isoelectric point in the first dimension and by molecular weight in the second dimension, followed by Western blotting with APC5 antibodies to resolve differently modified forms of the protein.

• Cell cycle synchronization combined with modification analysis: Synchronize cells at different cell cycle phases and analyze APC5 modifications to determine cell cycle-dependent regulation patterns.

• Kinase/ligase inhibitor studies: Treat cells with inhibitors of specific kinases or ubiquitin ligases before immunoprecipitating APC5 to determine which enzymes are responsible for specific modifications.

These approaches provide complementary information about the complex landscape of APC5 post-translational modifications and their functional significance.

How do I interpret unexpected bands in Western blots using APC5 antibodies?

Interpreting unexpected bands in APC5 Western blots requires systematic analysis following these methodological guidelines:

• Multiple antibody validation: Test multiple antibodies targeting different regions of APC5 to determine which bands are consistently detected across antibodies. In previous research, a panel of five antibodies (Ab5, H-290, Ab2, Ab6, Ab120) was used to validate band specificity . Consistent detection across antibodies increases confidence in band identity.

• Control-based comparison: Compare band patterns with those observed in control cell lines. For example, HCT116 and HEK293 express full-length APC (314 kDa), while SW480 expresses a truncated form (152-155 kDa) . This provides reference points for expected migration patterns.

• siRNA knockdown verification: Perform siRNA-mediated knockdown of APC5 and determine which bands decrease in intensity, confirming their identity as APC5-specific . Bands unaffected by knockdown likely represent cross-reactivity.

• Potential explanations for specific patterns:

  • Bands smaller than expected may represent degradation products or alternatively spliced isoforms

  • Bands larger than expected may indicate post-translational modifications or aggregation

  • Multiple bands of similar size may represent differently modified forms of the same protein

• Notable example interpretation: The study in the search results demonstrated that a 150 kDa protein consistently detected by multiple APC antibodies was unlikely to be APC , highlighting the importance of rigorous validation.

This systematic approach ensures accurate interpretation of band patterns and prevents misattribution of signals.

What are the common challenges in immunoprecipitation with APC5 antibodies and how can they be overcome?

Immunoprecipitation with APC5 antibodies presents several challenges that can be addressed through specific methodological refinements:

• Challenge: Low efficiency precipitation
  Solution: Optimize antibody amount (1-2 μg/ml has been effective ), incubation time (2-3 hours at 4°C), and bead type. Pre-clearing lysates with protein G beads reduces non-specific binding , and pre-blocking protein G beads with 3% milk for 1 hour improves specific capture .

• Challenge: Co-precipitation of non-specific proteins
  Solution: Include stringent washing steps (three washes in IP buffer has been effective ) and compare results with isotype control IPs (normal IgG) to identify true interactions versus background binding .

• Challenge: Interference from antibody heavy chains in Western blot detection
  Solution: Use light chain-specific or conformation-specific secondary antibodies for detection, or consider cross-linking the antibody to beads before IP to prevent antibody leaching.

• Challenge: Poor recovery of intact APC/C complex
  Solution: Use gentle lysis conditions that preserve protein-protein interactions (NP-40 or CHAPS-based buffers rather than stronger detergents like SDS) and keep samples at 4°C throughout the procedure to minimize complex dissociation.

• Challenge: Weak signals in subsequent Western blots
  Solution: Transfer immunoprecipitates in 2× Towbin buffer with 0.02% SDS or CAPS with 10% methanol to improve transfer efficiency . For high molecular weight proteins, perform overnight transfer at 600 mA .

These optimizations based on established protocols improve IP efficiency and specificity when working with APC5 antibodies.

How can I address specificity concerns when multiple proteins are detected by APC5 antibodies?

Addressing specificity concerns with APC5 antibodies requires a systematic approach to distinguish true signals from artifacts:

• Comprehensive antibody panel testing: Analyze samples with multiple antibodies targeting different regions of APC5. In previous research, researchers used five independently derived antibodies: four monoclonal antibodies (Ab2, Ab5, Ab6, and Ab120) and one polyclonal antibody (H-290) . This multi-antibody approach helped identify which signals were consistently detected across different antibodies.

• Sequential immunoprecipitation validation: Perform immunoprecipitation with one APC5 antibody and then detect the precipitated protein with a different APC5 antibody. This cross-validation approach confirms that different antibodies recognize the same protein species .

• RNA interference specificity confirmation: Implement siRNA-mediated knockdown of APC5 with multiple siRNAs targeting different regions of the gene. Compare with non-interfering siRNA controls to identify which protein bands specifically decrease with APC5 knockdown .

• Molecular weight analysis: Compare observed molecular weights with expected values. Full-length APC should be detected at approximately 314 kDa by validated antibodies, while alternative forms may have distinct sizes .

• Control cell lines: Include cell lines with known APC5 expression patterns. For example, HCT116 and HEK293 express full-length APC (314 kDa), while SW480 expresses a truncated form with a predicted size of 147 kDa (actual running size 152-155 kDa) .

These approaches collectively provide multiple lines of evidence to resolve specificity concerns and accurately identify bona fide APC5 signals.

What factors should be considered when comparing results from different APC5 antibodies?

When comparing results from different APC5 antibodies, consider these critical analytical factors:

• Epitope location differences: Antibodies targeting different regions of APC5 may yield varying results based on epitope accessibility. The search results mention antibodies raised against different regions, including a synthetic peptide near the center of human APC5 (amino acids 480-530) and others targeting N- and C-terminal regions . Epitope location can affect detection depending on protein conformation or interactions.

• Antibody format variations: Polyclonal antibodies detect multiple epitopes while monoclonal antibodies recognize single epitopes. The search results reference both types: rabbit polyclonal antibodies and monoclonal antibodies (Ab2, Ab5, Ab6, Ab120) . Polyclonals may provide stronger signals but potentially more background, while monoclonals offer higher specificity.

• Application-specific optimization: Antibodies optimized for different applications (WB, IF, IHC-P, ELISA) may perform inconsistently across techniques . An antibody performing well in Western blotting might not be optimal for immunofluorescence.

• Validation methodology differences: Compare the validation methods used for each antibody. Thoroughly validated antibodies (through siRNA knockdown, multiple antibody testing, etc.) provide more reliable results .

• Batch-to-batch variability: Particularly with polyclonal antibodies, batch-to-batch variations can affect performance. Maintain records of antibody lot numbers when comparing results across experiments.

• Experimental condition sensitivity: Different antibodies may have varying sensitivities to fixation methods, buffer conditions, or protein denaturation states. These factors should be standardized when making direct comparisons.

Awareness of these factors ensures appropriate interpretation when comparing results obtained with different APC5 antibodies.

How can APC5 antibodies be utilized in cancer research and what are the relevant considerations?

APC5 antibodies provide powerful tools for investigating cell cycle dysregulation in cancer through several sophisticated approaches:

• Comparative expression profiling: Use APC5 antibodies in immunohistochemistry or tissue microarrays to compare expression levels between normal tissues and tumors of various origins and stages. This can identify potential correlations with cancer progression or subtype classification. When analyzing human kidney tissue lysate, 15 μg of total protein yielded detectable APC5 signal , providing a reference point for optimizing tumor tissue analysis.

• Cell cycle checkpoint analysis: Apply APC5 antibodies in co-staining experiments with established cell cycle markers to investigate how APC/C function is altered in cancer cells with perturbed cell cycle control. Since APC/C regulates progression through mitosis and G1 phase , aberrations may contribute to genomic instability.

• Mechanistic studies of ubiquitination pathways: Leverage APC5 antibodies to investigate altered ubiquitination patterns in cancer cells. The APC/C complex mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lesser extent, 'Lys-48'- and 'Lys-63'-linked chains . Changes in these patterns might reveal dysregulated protein degradation contributing to oncogenesis.

• Therapeutic response monitoring: Use APC5 antibodies to track changes in APC/C complex activity following treatment with cell cycle-targeting therapeutics. This application requires optimized immunoprecipitation protocols similar to those used in previous studies .

• Cancer stem cell investigations: Apply APC5 antibodies in combination with stem cell markers to study cell cycle regulation in cancer stem cell populations, which may reveal unique vulnerabilities.

These applications require rigorous validation using the approaches described in previous sections, particularly when comparing results across different cancer types or treatment conditions.

What are the potential applications of APC5 antibodies in studying neurodegenerative diseases?

APC5 antibodies offer valuable research tools for investigating the relationship between cell cycle dysregulation and neurodegenerative diseases through several methodological approaches:

• Post-mitotic neuron cell cycle re-entry analysis: Though mature neurons are post-mitotic, inappropriate cell cycle re-entry has been implicated in neurodegeneration. APC5 antibodies can be used to examine changes in APC/C expression or activity in models of neurodegenerative disease, potentially revealing disruptions in this critical cell cycle regulator.

• Protein aggregation studies: Many neurodegenerative diseases feature protein aggregation. Since APC/C mediates ubiquitination and subsequent protein degradation , APC5 antibodies can help investigate whether impaired APC/C function contributes to reduced clearance of aggregation-prone proteins.

• Ubiquitination pattern analysis: The APC/C complex catalyzes formation of specific ubiquitin chain types, including 'Lys-11'-linked and branched 'Lys-11'-/'Lys-48'-linked chains . APC5 antibodies can be used to immunoprecipitate the complex from neural tissues to study alterations in these ubiquitination patterns in disease states.

• Comparative tissue expression studies: Use validated APC5 antibodies suitable for IHC-P to compare expression patterns between healthy and diseased brain tissue sections, potentially revealing region-specific changes in expression or localization.

• Protein-protein interaction networks: Apply co-immunoprecipitation with APC5 antibodies followed by mass spectrometry to identify altered interaction networks in neurodegenerative disease models, potentially revealing disease-specific interactors.

These applications require careful consideration of tissue-specific optimization, particularly for immunohistochemistry in brain tissue, which may require specialized fixation and antigen retrieval protocols.

How can multiplexed imaging techniques be combined with APC5 antibodies for advanced cell cycle studies?

Multiplexed imaging with APC5 antibodies enables sophisticated analysis of cell cycle regulation through these advanced methodological approaches:

• Multi-parameter immunofluorescence: Combine APC5 antibodies with antibodies against other cell cycle regulators and structural markers in multiplexed immunofluorescence panels. This approach requires careful selection of primary antibodies from different host species (rabbit polyclonal APC5 antibodies are documented ) to allow for species-specific secondary antibody detection without cross-reactivity.

• Cyclic immunofluorescence (CycIF): Implement iterative rounds of staining with different antibodies followed by imaging and fluorophore inactivation. This method allows for dramatically expanded multiplexing capability beyond traditional fluorescence channel limitations. APC5 antibodies can be incorporated into panels with numerous other markers to create high-dimensional datasets.

• Mass cytometry imaging (Imaging CyTOF): Conjugate APC5 antibodies with rare earth metals for use in mass cytometry imaging, which allows simultaneous visualization of dozens of proteins in tissue sections with subcellular resolution. This technique bypasses spectral overlap limitations of fluorescence microscopy.

• Spatial transcriptomic integration: Combine APC5 immunofluorescence with in situ RNA detection methods (e.g., RNAscope, MERFISH) to correlate protein expression with transcriptional states at the single-cell level, providing insights into regulatory mechanisms.

• Live-cell multiplexed imaging: For dynamic studies, combine fluorescently labeled APC5 antibody fragments with spectrally distinct probes for other cell cycle components, allowing real-time tracking of multiple factors during cell cycle progression.

These advanced imaging approaches require specialized equipment and careful optimization but provide unprecedented insights into the spatial and temporal dynamics of APC5 function in complex cellular contexts.